Abbott Laboratories Corporation

Other

Abbvie Inc.

John M Lipari

Dilip Kaul

Soumojeet Ghosh

Laman L Alani

Laman A Al-Razzak

Rong R Gao

Kennan C Marsh

Vanik D Petrossian

Richard H Whelan

Donald P Gauwitz

Dawn M Raymond

Tom Reiland

Hing L Sham

Dale J Kempf

Daniel W Norbeck

Xiaoqi Chen

David A Betebenner

Panayiotis P Constantinides

Thomas R Herrin

Gondi N Kumar

Yeshwant D Sanzgiri

Michelle A Long

Bashar Y Abdullah

Lisa L McChesney-Harris

A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.

Flavoring systems for pharmaceutical compositions and methods of making such compositions

The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one structured lipid as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.

Formulations comprising lipid-regulating agents

The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one monoglyceride as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.

The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one medium chain glycerol ester of a fatty acid as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.

A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Pharmaceutical composition

Retroviral protease inhibiting compounds

Binary pharmaceutical compositions comprising (i) a cyclosporine compound, (ii) a hydrophilic phase and (iii) a surfactant provide bioavailability of the active ingredient which is equivalent to that provided by ternary compositions, but without the need for a lipophilic phase.

Hydrophilic binary systems for the administration of lipophilic compounds

Beta-cyclodextrin forms a water-soluble complex or inclusion compound with steroid compounds having a molecular structure smaller than the interior cavity in the doughnut-shaped molecular structure of beta-cyclodextrin. The resulting inclusion compounds can be used for a variety of applications including aqueous topical ophthalmic preparations and topical dermatological ointments.

Water-soluble steroid compounds

Growing community of inventors

Racine, WI, United States of America

John M Lipari